• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

Id: 41: thrombotic ramifications of ophthalmologic diagnosis of familial and acquired thrombophilia as pathoetiology for otherwise unexplained uveitis.
Conclusion When the usual pathoetiologies of uveitis are not found, ophthalmologists should screen for thrombophilia, often being the first to illuminate treatable etiologies for other thrombotic events. In our 3 patients, when the pathoetiology of uveitis could not be discerned, screening for familial and acquired thrombophilia had important therapeutic ramifications in the probands and their first degree relatives. .
Source: Journal of Investigative Medicine - March 21, 2016 Category: Research Authors: Bruce, C., Dixon, S., Glueck, C., Wang, P., Hutchins, R. Tags: Genetic [amp ] Molecular Medicine Source Type: research